SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001420720-24-000012
Filing Date
2024-02-26
Accepted
2024-02-26 07:59:30
Documents
17
Period of Report
2024-02-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20240226x8k.htm   iXBRL 8-K 35574
2 EX-10.1 ibio-20240226xex10d1.htm EX-10.1 479574
3 EX-99.1 ibio-20240226xex99d1.htm EX-99.1 12929
  Complete submission text file 0001420720-24-000012.txt   727036

Data Files

Seq Description Document Type Size
4 EX-101.SCH ibio-20240226.xsd EX-101.SCH 4161
5 EX-101.DEF ibio-20240226_def.xml EX-101.DEF 3260
6 EX-101.LAB ibio-20240226_lab.xml EX-101.LAB 13977
7 EX-101.PRE ibio-20240226_pre.xml EX-101.PRE 10320
19 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20240226x8k_htm.xml XML 4621
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

IRS No.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 24673586
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)